公开(公告)号：US11639355B2

公开(公告)日：2023-05-02

申请号：US16979202

申请日：2019-03-12

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Xiaobing Yan ,  Jianglei Huang ,  Yuekun Nie ,  Guoping Hu ,  Jian Li ,  Shuhui Chen ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC分类号： C07D239/22 ,  C07D487/04 ,  A61P35/00 ,  C07D519/00

摘要： Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.

公开(公告)号：US10774081B2

公开(公告)日：2020-09-15

申请号：US16345271

申请日：2017-10-30

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

发明人： Jianyu Lu ,  Charles Z. Ding ,  Xu Zeng ,  Huijun He ,  Shuhui Chen ,  Lihong Hu ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC分类号： C07D471/04 ,  A61P35/00

摘要： Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.

公开(公告)号：US12098127B2

公开(公告)日：2024-09-24

申请号：US17295878

申请日：2019-10-17

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

发明人： Huijun He ,  Shenyi Shi ,  Jianyu Lu ,  Charles Z. Ding ,  Lihong Hu ,  Bin Shi ,  Wenqian Yang ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC分类号： C07D209/30

CPC分类号： C07D209/30 ,  C07B2200/13

摘要： Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

公开(公告)号：US11034653B2

公开(公告)日：2021-06-15

申请号：US16648943

申请日：2018-09-25

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

发明人： Huijun He ,  Jianyu Lu ,  Weidong Li ,  Shenyi Shi ,  Zhijuan Chen ,  Charles Z. Ding ,  Lihong Hu ,  Tie-Lin Wang ,  Jiaqiang Dong

IPC分类号： C07D209/18

摘要： Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.

公开(公告)号：US10519143B2

公开(公告)日：2019-12-31

申请号：US16087861

申请日：2017-03-24

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

发明人： Jianyu Lu ,  Charles Z. Ding ,  Lihong Hu ,  Huijun He ,  Shuhui Chen ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC分类号： A61K31/437 ,  C07D409/06 ,  C07D403/12 ,  A61K31/404 ,  C07D209/18 ,  C07D401/06 ,  C07D405/06 ,  A61P35/00

摘要： Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.